Intellectual Property Rights in Biotechnology

Learning Objectives

• Define patent, trademark, and trade secret protection and identify which applies to a given biotech asset.
• Explain the three legal requirements for patentability: novelty, non-obviousness, and utility.
• State what can and cannot be patented in biotechnology, citing Chakrabarty and Myriad Genetics.
• Describe how the Bayh-Dole Act changed ownership of publicly funded biotech inventions.
• Evaluate the trade-offs between patenting and trade secrecy for a biotech company.
• Apply IP concepts to real scenarios such as gene patents, CRISPR licensing, and biosimilars.

Quick Answer

Intellectual property (IP) rights let biotech companies and researchers control who can use their inventions — which is what makes it commercially viable to spend hundreds of millions of dollars developing a new drug or diagnostic test. The four main tools are patents (protect inventions like a new gene-editing method or a modified organism), trademarks (protect brand names like a drug's trade name), trade secrets (protect confidential know-how that isn't disclosed publicly), and copyrights (protect original written works and some software). Biotech IP is unusually contested because it decides whether genes, cell lines, and living organisms can be "owned" at all — a question courts are still refining.

Why Biotechnology Needs Intellectual Property Law

Developing a new drug can cost over a billion dollars and take more than a decade, most of which is spent on trials that fail. If a competitor could copy the winning drug the day it launched, no company would take that risk. IP law exists to solve this: it grants inventors a temporary, exclusive right to their invention in exchange for publicly disclosing how it works, so society still benefits from the knowledge even while the inventor recoups their investment.

Biotechnology sits in a strange position within IP law because its "inventions" are often built from living matter — organisms, genes, cells — which raises a question ordinary IP law never had to answer before: can nature itself be owned, or only what you do to it?

Patents: The Core Biotech IP Tool

A patent grants an inventor the exclusive right to make, use, sell, or license their invention for a fixed period (20 years from filing in most jurisdictions) in exchange for publicly disclosing exactly how the invention works. To be patentable, an invention must meet three tests:

1. Novelty — it must not already exist or be publicly known.
2. Non-obviousness — it must not be an unsurprising next step to someone skilled in the field.
3. Utility — it must have a specific, credible, real-world use.

In biotechnology, patents typically cover: genetically engineered organisms, recombinant proteins, diagnostic methods, gene-editing tools (like CRISPR-Cas9 systems), and complementary DNA (cDNA) constructs.

What you cannot patent: a naturally occurring gene sequence exactly as it exists in an organism, a law of nature, or an abstract idea. This line was drawn sharply by two US Supreme Court cases:

• Diamond v. Chakrabarty (1980): The Court ruled that a bacterium genetically engineered to break down crude oil was patentable because it was "a non-naturally occurring manufacture or composition of matter" — a human invention, not a product of nature. This case opened the door to patenting living organisms altered by human intervention.
• Association for Molecular Pathology v. Myriad Genetics (2013): The Court unanimously ruled that isolating a naturally occurring gene (in this case, the BRCA1/BRCA2 breast cancer genes) does not make it patentable, because merely isolating something doesn't create anything new. However, the Court held that cDNA — a synthetic version of the gene created by removing non-coding regions — IS patentable, because it doesn't exist in that exact form in nature.

Together, these cases give the modern rule: you can patent what you build; you cannot patent what you find.

Trademarks, Copyrights, and Trade Secrets

Trademarks protect brand identifiers — names, logos, slogans — that let customers recognize a company's products. In biotech, a company's drug brand name (like a specific therapeutic's trade name) is trademarked separately from the drug's underlying patent, which is why trademarks can outlast patents indefinitely as long as the brand keeps being used commercially.

Copyrights protect original expressive works — software code, databases, published papers, and documentation. In bioinformatics, copyright can protect original software tools, though the underlying algorithms may need patent protection to stop others from re-implementing the same method differently.

Trade secrets protect confidential information that gives a business a competitive edge — a proprietary cell line, an unpublished manufacturing process, or an internal dataset — as long as the company takes reasonable steps to keep it secret. Unlike a patent, a trade secret is never disclosed publicly and can in theory last forever, but it offers zero protection if a competitor independently discovers or reverse-engineers the same thing.

The strategic choice between patenting and trade secrecy is a real business decision: patenting requires public disclosure (so competitors learn your method once the patent issues) but gives strong, enforceable protection; trade secrecy keeps the method hidden indefinitely but offers no legal recourse if someone else figures it out independently. Coca-Cola's formula is trade secret; most drugs are patented, because reverse-engineering a drug's chemical structure is usually easy once it's on the market.

Ownership of Publicly Funded Research: The Bayh-Dole Act

Before 1980, inventions made using US federal research grants were typically owned by the government, which rarely commercialized them — most sat unused. The Bayh-Dole Act (1980) changed this by allowing universities, small businesses, and non-profits to retain ownership of inventions developed with federal funding and license them to industry. This single law is widely credited with launching the modern university tech-transfer and biotech-startup ecosystem, because it gave researchers and their institutions a financial incentive to commercialize discoveries rather than let them sit in a filing cabinet.

Global Frameworks

Biotech IP is not just national — it operates within international agreements:

• TRIPS Agreement (Trade-Related Aspects of Intellectual Property Rights, under the WTO): sets minimum IP protection standards that member countries must adopt, including for biotech and pharmaceutical patents.
• EU Biotechnology Directive: harmonizes what counts as patentable biological material across EU member states, generally excluding human cloning processes and unmodified human genes from patentability on ethical grounds.

Key Terms

Term	Definition
Patent	An exclusive, time-limited legal right to an invention, granted in exchange for public disclosure of how it works.
Novelty	A patentability requirement that the invention must not already be publicly known.
Non-obviousness	A patentability requirement that the invention must not be an obvious step for a skilled person in the field.
Utility	A patentability requirement that the invention must have a specific, credible practical use.
cDNA (complementary DNA)	Synthetic DNA made in a lab by copying only the coding regions of a gene's mRNA; patentable because it does not occur in that exact form in nature.
Trade secret	Confidential business information protected by keeping it secret rather than disclosing it publicly, with no fixed time limit.
Trademark	Legal protection for brand identifiers such as names, logos, and slogans.
Bayh-Dole Act	1980 US law allowing universities and small businesses to own and license inventions made with federal research funding.
TRIPS Agreement	WTO treaty setting minimum global standards for intellectual property protection, including in biotechnology.

Common Mistakes

Misconception 1: "You can patent any gene once you've sequenced it." Why it's wrong: Sequencing a naturally occurring gene is discovery, not invention — the gene existed before you found it. Correct view: Per Myriad Genetics (2013), a naturally occurring gene sequence, even once isolated, is not patentable; only human-made derivatives like cDNA, or specific diagnostic methods and modified versions built from that sequence, can be patented.

Misconception 2: "A patent and a trade secret protect the same thing, just differently." Why it's wrong: They protect fundamentally different situations. Correct view: A patent requires full public disclosure in exchange for a time-limited exclusive right; a trade secret requires the opposite — permanent confidentiality — and offers no protection at all if a competitor independently discovers the same information.

Misconception 3: "Universities can't own inventions made with government grant money." Why it's wrong: This was true before 1980. Correct view: The Bayh-Dole Act (1980) specifically reversed this, letting universities and small businesses retain ownership of federally funded inventions and license them commercially — this is why so many biotech startups spin out of university labs today.

Comparison and Connections

IP Tool	Protects	Disclosure Required?	Duration	Biotech Example
Patent	Inventions (methods, organisms, cDNA)	Yes, full public disclosure	~20 years from filing	CRISPR-Cas9 gene-editing patents
Trademark	Brand names, logos	Yes (registered publicly)	Indefinite, if renewed and used	A drug's trade name
Trade secret	Confidential processes/data	No, must stay secret	Indefinite, until disclosed/discovered	Proprietary cell-culture protocol
Copyright	Original written/software works	Yes (upon publication)	Life of author + ~70 years	Bioinformatics software/database

Practice Questions

Recall

1. Name the three legal requirements an invention must meet to be patentable. Answer guidance: Novelty, non-obviousness, and utility.
2. What did the Bayh-Dole Act (1980) change about ownership of federally funded research? Answer guidance: It allowed universities, small businesses, and non-profits to retain ownership of inventions made with federal grant money and license them commercially, rather than the government retaining ownership.

Understanding 3. Explain why cDNA is patentable but a naturally occurring gene sequence is not. Answer guidance: cDNA is synthesized by copying only a gene's coding regions from its mRNA — a form that does not exist naturally in the genome — so it counts as a human-made invention; the natural gene sequence is simply discovered, not invented. 4. Why might a company choose trade secrecy over patenting for a manufacturing process? Answer guidance: A trade secret never expires and requires no public disclosure, so if the process is hard to reverse-engineer, the company can protect it indefinitely — whereas a patent expires after ~20 years and requires disclosing exactly how the process works, letting competitors use it once the patent lapses.

Application 5. A university lab discovers a new antibody using a federal research grant. Who owns the invention, and why? Answer guidance: Under the Bayh-Dole Act, the university itself can own and patent the invention (rather than the federal government), and can then license it to a company for commercialization. 6. A biotech firm develops a novel gene sequence for an engineered yeast strain that produces insulin more efficiently. Is this patentable? Justify using relevant case law. Answer guidance: Yes — following the Chakrabarty precedent, the engineered yeast strain is a human-made composition of matter with a new function, not something occurring in nature, so it qualifies for patent protection.

Analysis 7. Compare the strategic risk of patenting versus trade secrecy for a company whose invention (a diagnostic algorithm) could be reverse-engineered by studying its outputs. Answer guidance: If the algorithm can be reverse-engineered from its outputs, trade secrecy is risky because a competitor could legally replicate it once figured out; patenting is safer here because even though the method is disclosed, only the patent holder has the legal right to use it, so reverse-engineering wouldn't give a competitor rights to exploit it. 8. Evaluate the ethical tension in gene patenting between rewarding innovation and treating genetic material as a commodity, using the Myriad Genetics case as evidence. Answer guidance: Patents incentivize the R&D needed to discover disease-linked genes and develop tests, but early gene patents (before Myriad) let single companies monopolize testing for genes like BRCA1/2, raising prices and limiting patient access; the Myriad ruling partially resolved this tension by keeping natural gene sequences in the public domain while still allowing patents on genuinely inventive derivatives like cDNA and novel diagnostic methods.

FAQ

Q1: Can I patent a virus or bacterium I found in nature? No. A naturally occurring organism, exactly as found, cannot be patented — only organisms you have genuinely altered through human intervention (like engineering new metabolic functions) qualify, per Chakrabarty.

Q2: How long does a biotech patent last? Typically 20 years from the filing date in most jurisdictions, though the effective commercial life is often shorter because years are spent in trials and regulatory approval before the product reaches market.

Q3: What happens to a drug's exclusivity when its patent expires? Other manufacturers can produce generic (or biosimilar, for biologics) versions, usually causing prices to fall sharply — this is why companies invest heavily in extending exclusivity through new formulations, uses, or follow-on patents.

Q4: Is CRISPR gene-editing technology patented? Yes, and it was the subject of a long, high-profile patent dispute between the Broad Institute and the University of California over who first invented the CRISPR-Cas9 system for use in eukaryotic cells, illustrating how contested and commercially valuable foundational biotech patents can be.

Q5: Why do universities license inventions to companies instead of manufacturing products themselves? Universities generally lack the capital, manufacturing infrastructure, and regulatory expertise to bring a product to market; licensing lets a company do that work in exchange for royalties, while the university (thanks to Bayh-Dole) still profits from and gets credit for the underlying invention.

Quick Revision

• IP law grants temporary exclusive rights in exchange for public disclosure, funding the cost of biotech R&D.
• Four main tools: patents (inventions), trademarks (brands), trade secrets (confidential know-how), copyrights (expressive works).
• Patentability requires novelty, non-obviousness, and utility.
• Chakrabarty (1980): engineered, human-made organisms ARE patentable.
• Myriad Genetics (2013): naturally occurring gene sequences are NOT patentable; cDNA IS.
• Rule of thumb: you can patent what you build, not what you find.
• Trade secrets never expire but offer no protection against independent discovery; patents expire (~20 years) but block all unauthorized use.
• Bayh-Dole Act (1980): let universities/small businesses own and license federally funded inventions, fueling the biotech startup boom.
• TRIPS sets global minimum IP standards; the EU Biotechnology Directive harmonizes patentability rules across EU states.
• Trademarks can outlast patents indefinitely as long as the brand remains in commercial use.
• Gene patent disputes (e.g., CRISPR) show how commercially valuable and contested foundational biotech IP can be.

Related Topics

Prerequisites: Introduction to Ethical and Legal Issues

Related Topics: Regulatory and Compliance Issues, Ethics in Genetic Research

Next Topics: Biosafety and Biosecurity, Case Studies in Bioethics